StockDuty ← Dashboard Aug 14, 2026 05:32 PM ET
CatalystCorporate

OUTLOOK THERAPEUTICS TARGETS MORE THAN $500M PEAK ANNUAL LYTENAVA SALES BY 2030 AS IT FORECASTS $50M-$75M FIRST-YEAR NET REVENUE - SEEKINGALPHA

$500M peak sales target and $50M-$75M first-year revenue forecast signal significant commercial upside.

What changed
$500M peak sales target and $50M-$75M first-year revenue forecast signal significant commercial upside.
Why it matters
$500M peak sales target and $50M-$75M first-year revenue forecast signal significant commercial upside. — impact context not separately stored; see What changed.
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →